Marker Therapeutics, Inc.

Category: Press Releases

TapImmune To Present at 2018 Janney Healthcare Conference

Peter L. Hoang will be presenting at the 2018 Janney Healthcare Conference.
Read More

TapImmune to Participate at Two Upcoming Industry Conferences

Peter L. Hoang will be participating in two industry conferences next week.
Read More

TapImmune Announces Pricing of $70 Million Private Placement

TapImmune today announced that it has entered into security purchase agreements with certain institutional and accredited investors in connection with a private placement of its equity securities. The private placement will be led by New Enterprise Associates (NEA) with participation from Aisling Capital and Perceptive Advisors, among other new and existing investors.
Read More

TapImmune to Present at the Jefferies 2018 Global Healthcare Conference

TapImmune today announced that its President and CEO, Peter L. Hoang, will present at the Jefferies 2018 Global Healthcare Conference taking place June 5-8, 2018, in New York City.
Read More

TapImmune to Present at 2018 Sachs Associates Immuno-Oncology BD&L and Investment Forum

TapImmune today announced that its President and CEO, Peter Hoang, will participate in a panel discussion and give a company presentation at the 2018 Sachs Associates Immuno-Oncology BD&L and Investment Forum, held June 1, 2018, at the Waldorf Astoria Chicago Hotel.
Read More

TapImmune to Host Investor Webinar on Thursday, May 24th to Discuss Proposed Merger with Marker Therapeutics and Its Transformational T Cell Therapy Platform

TapImmune Inc. (NASDAQ: TPIV) announced today that Peter Hoang, President and CEO, will host a video webinar and slide presentation to discuss the details of the proposed merger with Marker Therapeutics, Inc., on Thursday, May 24, 2018, at 4:05 p.m. EST. The webinar will be followed by a live Q&A session.
Read More

TapImmune Expands Scientific Advisory Board with Cancer Immunotherapy Pioneers James P. Allison, Ph.D., and Padmanee Sharma, M.D., Ph.D., from the MD Anderson Cancer Center

TapImmune today announced that it has expanded its recently formed Scientific Advisory Board (SAB), which will become effective in conjunction with the proposed merger between the Company and Marker Therapeutics, Inc., and will support the continued clinical development of the Company’s transformative, non-genetically engineered, multi-antigen T cell therapy platform.
Read More

TapImmune Creates Scientific Advisory Board to Support Clinical Development of Multi-Antigen Cell Therapy Platform

It is great to welcome renowned thought leaders Dr. Cliona M. Rooney, Dr. Helen Heslop, current president of the American Society for Gene and Cell Therapy, and former President of ASGCT, Dr. Malcolm Brenner to the Scientific Advisory Board that will become effective in conjunction with the proposed merger between TapImmune and Marker Therapeutics, Inc.
Read More

TapImmune to Host Investor Breakfast to Discuss Proposed Merger with Marker Therapeutics

TapImmune to Host Investor Breakfast to Discuss Proposed Merger with Marker Therapeutics
Read More

TapImmune and Marker Therapeutics Announce Entry into Merger Agreement, Creating a Transformational Immuno-Oncology Platform

TapImmune has entered into a definitive merger agreement to acquire Marker Therapeutics, Inc.
Read More